COST-EFFECTIVENESS OF DAPAGLIFLOZIN VERSUS SACUBITRIL/VALSARTAN FOR THE TREATMENT OF HEART FAILURE WITH REDUCED EJECTION FRACTION

被引：0
|
作者：
McEwan, P. [1 ]
Darlington, O. [1 ]
Bergenheim, K. [2 ]
Qin, L. [3 ]
机构：
[1] Hlth Econ & Outcomes Res Ltd, Cardiff, Wales
[2] AstraZeneca, Gothenburg O, Sweden
[3] AstraZeneca, Gaithersburg, MD USA
来源：
VALUE IN HEALTH | 2020年 / 23卷
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PCV45
引用
收藏
页码：S494 / S494
页数：1
相关论文
共 50 条
  • [1] Cost-effectiveness of sacubitril/valsartan in the treatment of heart failure with reduced ejection fraction
    McMurray, John J. V.
    Trueman, David
    Hancock, Elizabeth
    Cowie, Martin R.
    Briggs, Andrew
    Taylor, Matthew
    Mumby-Croft, Juliet
    Woodcock, Fionn
    Lacey, Michael
    Haroun, Rola
    Deschaseaux, Celine
    [J]. HEART, 2018, 104 (12) : 1006 - 1013
  • [2] Comparative Cost-Effectiveness of Sacubitril-Valsartan, Dapagliflozin, and Empagliflozin in Heart Failure With Reduced Ejection Fraction
    Parikh, Neil U.
    Dixit, Neal
    Ziaeian, Boback
    Fonarow, Gregg C.
    [J]. CIRCULATION, 2022, 146
  • [3] COST-EFFECTIVENESS OF SACUBITRIL/VALSARTAN IN THE TREATMENT OF HEART FAILURE WITH REDUCED EJECTION FRACTION IN SINGAPORE
    Declan, L.
    Tang, Z. X.
    Ng, C.
    Tan, J.
    Trueman, D.
    Woodcock, F.
    Cristino, J.
    [J]. VALUE IN HEALTH, 2018, 21 : S106 - S106
  • [4] Cost-effectiveness of sacubitril/valsartan versus enalapril in patients with heart failure and reduced ejection fraction
    Liang, Lin
    Wu, David Bin-Chia
    Aziz, Mohamed Ismail Abdul
    Wong, Raymond
    Sim, David
    Leong, Kui Toh Gerard
    Wei, Yong Quek
    Tan, Doreen
    Ng, Kwong
    [J]. JOURNAL OF MEDICAL ECONOMICS, 2018, 21 (02) : 174 - 181
  • [5] COST-EFFECTIVENESS OF SACUBITRIL/VALSARTAN IN HEART FAILURE WITH REDUCED EJECTION FRACTION IN SWEDEN
    Costa-Scharplatz, M.
    Lang, A.
    McMurray, J. J.
    Woodcock, F.
    Haroun, R.
    Johansson, D.
    Lund, L. H.
    [J]. VALUE IN HEALTH, 2016, 19 (07) : A650 - A651
  • [6] The cost-effectiveness of sacubitril/valsartan in chronic heart failure with reduced ejection fraction
    Mcmurray, J. J. V.
    Cowie, M. R.
    Briggs, A.
    Taylor, M.
    Hancock, E.
    Trueman, D. David
    Haroun, R.
    Deschaseaux, C.
    [J]. EUROPEAN JOURNAL OF HEART FAILURE, 2016, 18 : 276 - 276
  • [7] THE COST-EFFECTIVENESS OF SACUBITRIL/VALSARTAN IN THE TREATMENT OF CHRONIC HEART FAILURE WITH REDUCED EJECTION FRACTION IN TURKEY
    Sarioz, F.
    Ozdemir, O.
    Direk, S.
    Caglar, P.
    Ar, I
    [J]. VALUE IN HEALTH, 2017, 20 (09) : A616 - A616
  • [8] Cost-effectiveness of sacubitril/valsartan for the treatment of patients with heart failure with reduced ejection fraction in Portugal
    Borges, Margarida
    Afonso-Silva, Marta
    Laires, Pedro A.
    Gouveia, Miguel
    Alarcao, Joana
    Ascencao, Raquel
    Costa, Joao
    [J]. EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2020, 20 (02) : 199 - 205
  • [9] RE: Cost-effectiveness of sacubitril/valsartan versus enalapril in patients with heart failure and reduced ejection fraction
    Cristino, Joaquim
    Tang, Immanuel
    Ng, Caroline
    Tan, Jonathan
    Trueman, David
    Lee, Declan
    [J]. JOURNAL OF MEDICAL ECONOMICS, 2018, 21 (12) : 1145 - 1147
  • [10] Reply: Cost-effectiveness of sacubitril/valsartan versus enalapril in patients with heart failure and reduced ejection fraction
    Liang, Lin
    Wu, David Bin-Chia
    Aziz, Mohamed Ismail Abdul
    Wong, Raymond
    Sim, David
    Leong, Kui Toh Gerard
    Wei, Yong Quek
    Tan, Doreen
    Ng, Kwong
    [J]. JOURNAL OF MEDICAL ECONOMICS, 2018, 21 (12) : 1148 - 1149
12345